IRB #

STUDY00020969

Title

A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Principal Investigator

Lara Davis

Study Purpose

The purpose of this study is to study the effects, good and bad, of the study drug tazemetostat in combination with doxorubicin on participants and their epithelioid cancer.

Medical Condition(s)

soft tissue sarcoma, epithelioid tumors

Eligibility Criteria

Must be 18 years or older. Tests and procedures including blood tests, scanning, and a routine physical will be done before you can start to study to see if you are eligible.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

For the phase 1b portion, subjects may continue to receive study treatment until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study.
For the phase 3 portion, subjects will remain on treatment for an average of 10 months.

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

Epizyme, Inc.

Recruitment End

06/01/2023

Compensation Provided

No


Go Back